1 / 21

When will the diagnosis of Circulating tumor cells (CTC) help to patients?

When will the diagnosis of Circulating tumor cells (CTC) help to patients?. M artin Pešta, O ndřej Topolčan Department of Internal Medicine II, Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic. What we know today.

gizi
Download Presentation

When will the diagnosis of Circulating tumor cells (CTC) help to patients?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. When will the diagnosis of Circulating tumor cells (CTC) help topatients? Martin Pešta, Ondřej Topolčan Department of Internal Medicine II, Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic

  2. What we know today ● Circulating tumor cells (CTC) are present in peripheral blood of many patients with advanced stage ofcancer ● The number of CTC isin relation to prognosis of cancer ● Reducing number of CTCs after chemotherapy is in relation to responseto treatment ●It is possible to perform various phenotypic analysis (proteins and nucleic acids)of isolated CTC

  3. What should bring assessment of CTC to patients ● Detectionof CTC would helpdetermine: - early detection of cancer relapse (therapy monitoring) - the choice of cancer therapy  The patient wants to know how he's doing  The doctor wants to know what treatment to use

  4. By detection of CTC can be obtainedinformation: ● Identification number (enumeration) of circulating tumor cells ● Identification of phenotype of CTC

  5. CTC ● Are circulating tumor cells - biomarker on their own?or ●Are circulating tumor cells the substrateto determine biomarker / s?

  6. Incomplete definition of CTC by the FDA

  7. Epithelial-mesenchymaltransition (EMT) ●The dynamic process of transformation of epithelial cells into mesenchymal through a special transcriptionprogram ●During the EMT is transformed phenotype of cells- The release of intercellular connections- Change in expression of surface receptors- Reorganization of the cytoskeleton- Significantly increases cell motility- Loss cadherinexpression and the ability of cells to survive in the absence ofextracellular matrix components (support antiapoptotic activity) ●In the process of EMT are produced cells with properties of stem cells: - EMT byproducing of cancer stem cell retains the ability to self-renewal for the development of metastases

  8. Tumor stem cells (CSC) ●Origin and development of CSC is a multifactorial process - starting cellsfordevelopment CSC are tissue-specific stem cells - a series of genetic and epigenetic changes activate signaling pathways managing the process of self-renewal, transformation and tumor dedifferentiation ●Model CSC - tumor activity and growth are controlled by only a small part(less than 1%) of tumor cells with the ability to self- renewal,resistance to apoptosis and increased ability to repair DNA

  9. Analysis of chromosomes (Her2, TMPRSS-ETS) Number of CTC Analysis of RNA expression Analysis of DNA Determination of CTC phenotype CTC phenotype - protein (Her2, EGFR, AR)

  10. CTC diagnostic is suitable only for the diagnostics of certain cancer

  11. Current CTC isolationmethods according to achieve the level of testing for clinical useprepared by:Mark Carle Connelly, Ph.D.Veridex, LLC – Ortho Clinical Diagnostics

  12. Epic HD-CTC (EPIC, CA USA) ● "pathological approach" - blood smear on a slide – microscope evaluation ● Marking CK +, CD45-, DAPI + ● "accepted pathologists' ● Central collection, detection in laboratory, determination to 24h ● Benefits: - detection CTC doublets to large clusters CTC - You can add additional antibodies

  13. Microchannel platform (Biocept, USA) ● Blood pressure flows through the chip with antibodies, in which are CTC captured

  14. Microchannel platform (Biocept, USA) ● Visualization and enumeration of CTCs in the plate● Following the analysis of CTC phenotype (eg, cytogenetics,molecular biology)

  15. CTC detection using Photoacoustic flow cytometry ● Photoacoustic flow cytometry is used to detectionCTC sound reverberation (echo) from tumor cells ● Photoacoustic flow cytometry monitors cells circulating in vivo ● It is currently being developed for the detection of circulatingmelanoma tumor cells (CMC) ● Sound reflection is made ​​possible by the presence of melanin incells The method is developedbe John A. Viator, Ph.D. Departments of Biological Engineering and Dermatology University of Missouri, Columbia http://kolbe.missouri.edu/Welcome.html

  16. CTC detection using Photoacoustic flow cytometry

  17. Problems associated with the clinical application of CTC ● Have all detectedCTC the same metastaticpotential? ● To what extent is the determination of CTC reproducibile? ● Conduct of clinical trials is necessary ● Each platform provides different results

  18. Conclussion ●Answering and resolving these problems allows correct interpretation of results and subsequent diagnostic CTC use in treating cancer patients. ●Already existing diagnostic results CTC particularly in patients with breast cancer has shown to be beneficial. Understanding the biology of CTCshould provide a more accurate choice of treatment, cure or prolongation of life.

  19. Thank you for your attention!

More Related